NPPC and achondroplasia: Fibroblast growth factor receptor 3 (<i>FGFR3)</i> is a direct target of SHOX, and <i>FGFR3</i> mutations cause achondroplasia, a condition treatable with C-type natriuretic peptide (CNP) analogues.